Have adequate organ function as indicated by laboratory values.
Absence of severe comorbidities that in the opinion of the investigator might hamper participation in the study and/or treatment administration.
Participants must sign approved informed consent form (ICF).
You may not be if
Evidence of disease.
Prior treatment with anti-programmed cell death protein 1 and anti-PD-L1/2 modulating agents in adjuvant setting.
History or presence of immune-mediated disorders.
Participants with type 1 diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, or skin disorders not requiring systemic treatment are permitted to enroll.
Participant has positive screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or hepatitis C (HCV).
History of congenital immunodeficiency diseases, prior allogeneic stem cell transplantation, or organ transplantation.
History of any other malignancy other than NSCLC within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, papillary thyroid cancer treated with surgery, etc.
Known clinically significant history of liver disease consistent with Child-Pugh Class B or C, including active viral or other hepatitis virus, current alcohol abuse or cirrhosis.
Surgery or chemotherapy-related toxicity not resolved to grade 1 with the exception of grade ≤ 2 alopecia, fatigue, neuropathy, and lack of appetite/nausea.
Woman of childbearing potential who is pregnant or is breast feeding.
Woman of childbearing potential who is not consenting to use highly effective methods of birth control.
Man with a partner of childbearing potential who does not consent to use highly effective methods of birth control.
Participant has known hypersensitivity to monoclonal antibodies or to any of the excipients of the investigational product (IP).
Active cardiac disease or history of cardiac dysfunction, that in the judgment of the investigator would place the participant at additional risk when participating in the study.
Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current neumonitis/interstitial lung disease.
Live vaccine therapy within 4 weeks prior to IP administration.
Participation in another investigational drug study within 30 days prior to IP administration.
